Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease

Key Points

• This research aims to evaluate the efficacy and safety of the AAV8-tATP7B vector for treating Wilson’s disease.
• Conducted preclinical pharmacology and toxicology assessments of AAV8-tATP7B.
• Evaluated vector efficacy in relevant animal models.
• Assessed safety profiles through toxicological studies.
• AAV8-tATP7B demonstrated effective targeting and correction of Wilson’s disease pathology.
• Safety assessments indicated a favorable profile with minimal adverse effects.